OTLK Stock Forecast & Price Target

Outlook Therapeutics is positioned favorably because it has already secured marketing authorization in the European Union and United Kingdom for LYTENAVA, with commercial launches in the U.K., Germany, and Austria and additional expansion planned, creating an early revenue base in a large wet AMD market. The FDA appeal win in May 2026, June 1, 2026 BLA resubmission, and expected decision within 60 days materially de-risk the U.S. opportunity, while management’s guidance for first-year U.S. sales of $50 million to $75 million and potential annual U.S. sales above $500 million by 2030 underscore meaningful upside. Despite Q3 FY26 revenue of about $0 million and $14 million in cash versus $18 million in debt, the company’s improving reimbursement strategy, lean commercial buildout, and differentiated ophthalmic bevacizumab profile support a constructive fundamental outlook.

Outlook Therapeutics is burdened by repeated FDA setbacks, including CRLs on August 30, 2023, August 28, 2025, and December 31, 2025, which signal persistent regulatory and evidentiary concerns around ONS-5010 rather than a straightforward approval path. Although the NORSE TWO trial met safety and efficacy endpoints, the agency still cited CMC deficiencies, manufacturing inspection observations, and ultimately a lack of substantial evidence of effectiveness, forcing resubmissions in February 2025 and November 2025 and prolonging uncertainty. These repeated delays heighten liquidity and commercialization risk for a clinical-stage company dependent on a single lead asset, while also exposing it to reimbursement, competitive, and biotech sentiment pressures.